Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor
暂无分享,去创建一个
J. Manola | J. Desai | J. Folkman | J. Heymach | R. Maki | C. Baum | D. Shalinsky | J. Force | S. Deprimo | P. Beaudry | C. Bello | G. Demetri | A. Norden-Zfoni | J. Heymach
[1] A. Goldhirsch,et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. , 2006, Blood.
[2] R. Jain,et al. Differential circulation kinetics during antiangiogenic therapy of four distinct blood cell populations expressing endothelial markers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] E. Voest,et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] F Dignat-George,et al. Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry , 2006, Cytometry. Part B, Clinical cytometry.
[5] Ma Dong,et al. Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .
[6] R. Figlin,et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] E. Raymond,et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Drevs,et al. Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors , 2005 .
[9] J. Desai,et al. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST) , 2005 .
[10] J. Desai,et al. Pharmacodynamic analysis of target receptor tyrosine kinase activity and apoptosis in GIST tumors responding to therapy with SU11248 , 2005 .
[11] J. Folkman,et al. Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity , 2005, Clinical Cancer Research.
[12] J. Wood,et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] B. Peters,et al. Contribution of bone marrow–derived endothelial cells to human tumor vasculature , 2005, Nature Medicine.
[14] Randy Allred,et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.
[15] R. D'Amato,et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. , 2005, Cancer cell.
[16] J. Góra‐Tybor,et al. Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia. , 2005, European cytokine network.
[17] D. Hicklin,et al. Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies , 2004, Cancer Research.
[18] A. D. Van den Abbeele,et al. Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas , 2004, Clinical Cancer Research.
[19] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[20] David M Jablons,et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] D. Hicklin,et al. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. , 2004, Molecular cancer research : MCR.
[22] Ricky T. Tong,et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.
[23] R. Herbst,et al. Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors , 2004, Clinical Cancer Research.
[24] Binodh DeSilva,et al. Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules , 2003, Pharmaceutical Research.
[25] J. Manola,et al. Phase II Study of the Antiangiogenic Agent SU 5416 in Patients with Advanced Soft Tissue Sarcomas , 2004 .
[26] E. Voest,et al. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] J. Folkman,et al. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. , 2003, Cancer research.
[28] A. B. Lyons,et al. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors , 2003, Leukemia.
[29] N. Perelman,et al. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. , 2003, Blood.
[30] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[31] H. Kantarjian,et al. Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. , 2003, Leukemia research.
[32] T. Robak,et al. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. , 2003, European cytokine network.
[33] R. Herbst,et al. Surrogate markers in antiangiogenesis clinical trials , 2003, British Journal of Cancer.
[34] Juthamas Sukbuntherng,et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] Rachel Jones. Ecstasy danger hits the headlines , 2002, Nature Reviews Neuroscience.
[36] Koichi Hattori,et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? , 2002, Nature Reviews Cancer.
[37] A. Stopeck,et al. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[38] S. Rafii,et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment , 2002, Nature Medicine.
[39] C. Verfaillie,et al. Origin of endothelial progenitors in human postnatal bone marrow. , 2002, The Journal of clinical investigation.
[40] A. Krettek,et al. Expression of PDGF receptors and ligand-induced migration of partially differentiated human monocyte-derived macrophages: Influence of IFN-γ and TGF-β , 2001 .
[41] G. Pruneri,et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. , 2001, Cancer research.
[42] A. Goldhirsch,et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. , 2001, Blood.
[43] S. Rafii,et al. Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells , 2001, The Journal of experimental medicine.
[44] K. Shitara,et al. and surface marker for the lineage of monocyte-macrophages in humans Flt-1 , vascular endothelial growth factor receptor 1 , is a novel cell , 2001 .
[45] A. Harris,et al. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[46] G. Martiny-Baron,et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. , 2000, Cancer research.
[47] J. Isner,et al. VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. , 2000, The Annals of thoracic surgery.
[48] S. Rafii,et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. , 2000, Blood.
[49] R. Hebbel,et al. Origins of circulating endothelial cells and endothelial outgrowth from blood. , 2000, The Journal of clinical investigation.
[50] J. Isner,et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow‐derived endothelial progenitor cells , 1999, The EMBO journal.
[51] R. Hebbel,et al. Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells. , 1999, Blood.
[52] E. Wayner,et al. Circulating activated endothelial cells in sickle cell anemia. , 1997, The New England journal of medicine.
[53] A. Mantovani,et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. , 1996, Blood.
[54] U. Testa,et al. Multi-level effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors. , 1995, Blood.
[55] Y. Yazaki,et al. Expression of platelet-derived growth factor beta receptor on human monocyte-derived macrophages and effects of platelet-derived growth factor BB dimer on the cellular function. , 1993, The Journal of biological chemistry.